НовостиBenzingaBarclays Maintains Overweight on Medline, Lowers Price Target to $43 Barclays Maintains Overweight on Medline, Lowers Price Target to $43 Benzinga 2026.10.09 14:55 (GMT+0) Открыть на Benzinga Другие новости